DoH Policies screened during the period: 1st October 2018-31st December 2018
Topics:
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact assessment (EQIA).
Documents
- NICE Technology Appraisal TA539 - Lutetium (177lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
- NICE Technology Appraisal TA541 - Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
- NICE Technology Appraisal TA542 - Cabozantinib for untreated advanced renal cell carcinoma
- NICE Technology Appraisal TA543 - Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE Clinical Guideline NG97 - Dementia: assessment, management and support for people living with dementia and their carers (updates & replaces CG42 & partially updates TA217)
- NICE Clinical Guideline NG98 - Hearing loss in adults: assessment and management
- NICE Clinical Guideline NG99 - Brain tumours (primary) and brain metastases in adults
- NICE Clinical Guideline NG100 - Rheumatoid arthritis in adults: management (updates and replaces CG79)
- NICE Technology Appraisal TA544 - Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
- NICE Clinical Guideline NG104 – Pancreatitis
- NICE Clinical Guideline NG101 - Early and locally advanced breast cancer: diagnosis and management (updates and replaces CG80 and TAs 107, 108, 109 and 112)
- NICE Clinical Guideline NG106 - Chronic heart failure in adults: diagnosis and management (updates and replaces CG108)
- NICE Technology Appraisal TA545 - Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
- NICE Technology Appraisal TA546 - Padeliporfin for untreated localised prostate cancer
- NICE Clinical Guideline NG107 - Renal replacement therapy and conservative management (updates and replaces CG125 and TA48)
- NICE Technology Appraisal TA547 - Tofacitinib for moderately to severely active ulcerative colitis
- Rescheduling of cannabis-based medicinal products under Misuse of Drugs legislation